Search

Your search keyword '"Vassal, Gilles"' showing total 1,152 results

Search Constraints

Start Over You searched for: Author "Vassal, Gilles" Remove constraint Author: "Vassal, Gilles"
1,152 results on '"Vassal, Gilles"'

Search Results

1. AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial

2. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART

3. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer

5. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

6. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

8. Solutions for optimal care and research for children and adolescents with extremely rare cancers developed within the Joint Action for Rare Cancers (JARC)

9. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

10. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

13. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

14. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

15. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

18. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation

19. The Organization of Care in Pediatric Radiotherapy across SIOP Europe affiliated centers: A multicenter survey in the Framework of the 'Joint Action on Rare Cancers' project

20. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

22. Supplementary Table S4 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

23. Data from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

24. Supplementary Figure S1 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

25. Chemo-Immunotherapy with Dinutuximab Beta in Patients with Progressive High-Risk Neuroblastoma: Does Chemotherapy Backbone Matter?

26. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

27. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

28. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development

30. The ‘Survivorship Passport’ for childhood cancer survivors

31. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer

35. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study

36. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

37. Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models

40. From class waivers to precision medicine in paediatric oncology

41. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

42. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review

43. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

44. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

46. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus.

49. Abstract CT088: Phase I/II study of the PARP inhibitor olaparib in combination with irinotecan in children with advanced malignancies: arm D of the AcSé-ESMART trial

50. Abstract CT087: Phase I/II study of the WEE1 inhibitor adavosertib in combination with carboplatin in children with advanced malignancies: arm C of the AcSé-ESMART trial

Catalog

Books, media, physical & digital resources